Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of BC-819 in Patients With Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin

NCT03719300 is registered in ClinicalTrials.gov with Anchiano Therapeutics Israel Ltd. as lead sponsor.

NCT NCT03719300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03719300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of BC-819 in Patients With Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
March 20, 2019
Completion date
December 18, 2019
Enrollment
32 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer (nmibc)